TY - JOUR
T1 - Circulating fibrosis biomarkers and risk of atrial fibrillation
T2 - The Cardiovascular Health Study (CHS)
AU - Rosenberg, Michael A.
AU - Maziarz, Marlena
AU - Tan, Alex Y.
AU - Glazer, Nicole L.
AU - Zieman, Susan J.
AU - Kizer, Jorge R.
AU - Ix, Joachim H.
AU - Djousse, Luc
AU - Siscovick, David S.
AU - Heckbert, Susan R.
AU - Mukamal, Kenneth J.
N1 - Funding Information:
This research was supported by Contracts HHSN268201200036C, HHSN268200800007C, N01 HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and Grant HL080295 from the National Heart, Lung, and Blood Institute , with additional contribution from the National Institute of Neurological Disorders and Stroke. Additional support was provided by AG023629 from the National Institute on Aging . A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. M.A.R. was also supported by the Postdoctoral Research Fellowship Award of the Heart Rhythm Society. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the manuscript, and its final contents.
PY - 2014/5
Y1 - 2014/5
N2 - Background Cardiac fibrosis is thought to play a central role in the pathogenesis of atrial fibrillation (AF). Retrospective studies have suggested that circulating fibrosis biomarkers are associated with AF, but prospective studies are limited. Methods We measured circulating levels of 2 fibrosis biomarkers, procollagen type III, N-terminal propeptide (PIIINP) and transforming growth factor β1 among participants of the CHS, a population-based study of older Americans. We used Cox proportional hazards and competing risks models to examine adjusted risk of incident AF over a median follow-up of 8.8 years. Results Levels of PIIINP were assessed in 2,935 participants, of whom 767 developed AF. Compared with the median PIIINP level (4.45 μg/L), adjusted hazard ratios (95% CIs) were 0.85 (0.72-1.00) at the 10th percentile, 0.93 (0.88-0.99) at the 25th percentile, 1.04 (0.95-1.04) at the 75th percentile, and 1.07 (0.90-1.26) at the 90th. Transforming growth factor β1 levels, assessed in 1,538 participants with 408 cases of incident AF, were not associated with AF risk. Conclusion In older adults, PIIINP levels were associated with risk of incident AF in a complex manner, with an association that appeared to be positive up to median levels but with little relationship beyond that. Further studies are required to confirm and possibly delineate the mechanism for this relationship.
AB - Background Cardiac fibrosis is thought to play a central role in the pathogenesis of atrial fibrillation (AF). Retrospective studies have suggested that circulating fibrosis biomarkers are associated with AF, but prospective studies are limited. Methods We measured circulating levels of 2 fibrosis biomarkers, procollagen type III, N-terminal propeptide (PIIINP) and transforming growth factor β1 among participants of the CHS, a population-based study of older Americans. We used Cox proportional hazards and competing risks models to examine adjusted risk of incident AF over a median follow-up of 8.8 years. Results Levels of PIIINP were assessed in 2,935 participants, of whom 767 developed AF. Compared with the median PIIINP level (4.45 μg/L), adjusted hazard ratios (95% CIs) were 0.85 (0.72-1.00) at the 10th percentile, 0.93 (0.88-0.99) at the 25th percentile, 1.04 (0.95-1.04) at the 75th percentile, and 1.07 (0.90-1.26) at the 90th. Transforming growth factor β1 levels, assessed in 1,538 participants with 408 cases of incident AF, were not associated with AF risk. Conclusion In older adults, PIIINP levels were associated with risk of incident AF in a complex manner, with an association that appeared to be positive up to median levels but with little relationship beyond that. Further studies are required to confirm and possibly delineate the mechanism for this relationship.
UR - http://www.scopus.com/inward/record.url?scp=84899525953&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899525953&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2014.01.010
DO - 10.1016/j.ahj.2014.01.010
M3 - Article
C2 - 24766983
AN - SCOPUS:84899525953
SN - 0002-8703
VL - 167
SP - 723-728.e2
JO - American heart journal
JF - American heart journal
IS - 5
ER -